Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1752-1947
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report ; volume:13 ; number:1 ; day:26 ; month:12 ; year:2019 ; pages:1-4 ; date:12.2019
Journal of medical case reports ; 13, Heft 1 (26.12.2019), 1-4, 12.2019
- Urheber
-
Ohtani, Toshiyuki
Sintoku, Ryosuke
Yajima, Tasuku
Kaneko, Naoyuki
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13256-019-2326-y
- URN
-
urn:nbn:de:101:1-2020032710555798356797
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ohtani, Toshiyuki
- Sintoku, Ryosuke
- Yajima, Tasuku
- Kaneko, Naoyuki
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pharmacokinetics and thrombolytic effects of the recombinant tissue-type plasminogen activator in horses
Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report
A Fibrinogen‐Mimicking, Activated‐Platelet‐Sensitive Nanocoacervate Enhances Thrombus Targeting and Penetration of Tissue Plasminogen Activator for Effective Thrombolytic Therapy
Die Bedeutung der Plasminogenaktivatoren tissue-type-plasminogen activator und urokinase-type plasminogen activator für den Ischämie-Reperfusionsschaden
Idarucizumab: A novel antidote for reversal of dabigatran
Bone Marrow Plasminogen Activator in Malignant Disease
Tissue Plasminogen Activator Induced Delayed Edema in Experimental Porcine Intracranial Hemorrhage: Reduction with Plasminogen Activator Inhibitor-1 Administration
Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy
Urokinase-type plasminogen activator receptor in vascular calcification
Isolation and Properties of Human Vascular Plasminogen Activator
Influence of delivery on plasminogen activator inhibitor activity
Purification and Some Properties of Tissue Plasminogen Activator
Pharmacokinetics and thrombolytic effects of the recombinant tissue-type plasminogen activator in horses
Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report
A Fibrinogen‐Mimicking, Activated‐Platelet‐Sensitive Nanocoacervate Enhances Thrombus Targeting and Penetration of Tissue Plasminogen Activator for Effective Thrombolytic Therapy
Die Bedeutung der Plasminogenaktivatoren tissue-type-plasminogen activator und urokinase-type plasminogen activator für den Ischämie-Reperfusionsschaden
Idarucizumab: A novel antidote for reversal of dabigatran
Bone Marrow Plasminogen Activator in Malignant Disease
Tissue Plasminogen Activator Induced Delayed Edema in Experimental Porcine Intracranial Hemorrhage: Reduction with Plasminogen Activator Inhibitor-1 Administration
Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy
Urokinase-type plasminogen activator receptor in vascular calcification
Isolation and Properties of Human Vascular Plasminogen Activator
Influence of delivery on plasminogen activator inhibitor activity
Purification and Some Properties of Tissue Plasminogen Activator
Pharmacokinetics and thrombolytic effects of the recombinant tissue-type plasminogen activator in horses
Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report
A Fibrinogen‐Mimicking, Activated‐Platelet‐Sensitive Nanocoacervate Enhances Thrombus Targeting and Penetration of Tissue Plasminogen Activator for Effective Thrombolytic Therapy
Die Bedeutung der Plasminogenaktivatoren tissue-type-plasminogen activator und urokinase-type plasminogen activator für den Ischämie-Reperfusionsschaden
Idarucizumab: A novel antidote for reversal of dabigatran
Bone Marrow Plasminogen Activator in Malignant Disease
Tissue Plasminogen Activator Induced Delayed Edema in Experimental Porcine Intracranial Hemorrhage: Reduction with Plasminogen Activator Inhibitor-1 Administration
Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy
Urokinase-type plasminogen activator receptor in vascular calcification
Isolation and Properties of Human Vascular Plasminogen Activator
Influence of delivery on plasminogen activator inhibitor activity